Search results

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

Octave Specialty Group, Inc. OSG reported a second-quarter 2026 adjusted loss of 4 cents per share, narrower than the year-ago loss of 22 cents but wider than the Zacks Consensus Estimate of a

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

Sprouts Farmers Market, Inc. SFM reported second-quarter 2026 results, wherein the top line marginally missed the Zacks Consensus Estimate, while the bottom line beat the mark. The company continued

Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively.

Wall Street’s

The Coca-Cola Company KO has reported second-quarter 2026 results, with the top and bottom lines surpassing the Zacks Consensus Estimate. The company’s revenues and earnings per share (EPS) improved

Corteva, Inc. CTVA reported second-quarter 2026 results, wherein the top line missed the Zacks Consensus Estimate, while the bottom line beat the same. Earnings increased year over year, while net

Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.86. In the year-ago quarter, the company had

Columbia Sportswear Company COLM reported second-quarter 2026 results, with the top line beating the Zacks Consensus Estimate and the bottom line matching the same. Net sales increased year over